Can-Fite BioPharma Ltd.: Form 20-F for the period ended Dec 31, 2019
Filed with the SEC on Mar 27, 2020 and accepted by EDGAR at Mar 27, 2020, 16:26 ET.
Sections
Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 12 months2019-01-01 to 2019-12-31 | $11.0m | us-gaap:ResearchAndDevelopmentExpense |
| Shares outstanding | At period end2019-12-31 | 120,652,683 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0001213900-20-007682. Last ingested by Listed: Nov 2, 2026, 07:04 ET. Listed shows no prices and gives no investment advice.